Quarterly report pursuant to Section 13 or 15(d)

Statements of Cash Flows (Unaudited)

v3.7.0.1
Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Cash Flows from Operating Activities:    
Net loss $ (329) $ (332)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 4 0
Stock-based compensation 110 2
Deferred CEO compensation 38 0
Change in fair value of warrant liability (1,059) 0
Gain in settlement of liability (149) 0
Changes in operating assets and liabilities:    
Prepaid expenses (55) 0
Accounts payable and accrued expenses 49 40
Net Cash Used in Operating Activities (1,391) (290)
Cash Flows from Investing Activities:    
Investment in note receivable - Moleculin, LLC 0 (30)
Net Cash Used in Investing Activities 0 (30)
Cash Flows from Financing Activities:    
Proceeds from notes payable 0 165
Proceeds from exercise of warrants 805 0
Proceeds from sale of common stock, net of cash stock issuance costs 4,460 387
Net Cash Provided by Financing Activities 5,265 552
Net change in cash and cash equivalents 3,874 232
Cash and cash equivalents, at beginning of period 5,007 28
Cash and cash equivalents, at end of period 8,881 260
Supplemental disclosures of cash flow information:    
Cash paid for interest 0 0
Cash paid for income taxes 0 0
Supplemental disclosure of non-cash investing and financing activities:    
Common stock issued for conversion of debt 190 0
Common stock issued for services provided $ 89 $ 0